by jtcir-auto | Jun 13, 2022 | Press Releases
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”) – Positive results presented at the 13th International Congress on Autoimmunity being held...
by jtcir-auto | Jun 9, 2022 | Press Releases
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing...
by jtcir-auto | May 25, 2022 | Press Releases
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | May 18, 2022 | Press Releases
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | May 16, 2022 | Press Releases
TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...